NCT01520207View on ClinicalTrials.gov

Mannitol - Potential Role in Hemodialysis Initiation for Reduction of Intra-dialytic Hypotension

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

July 31, 2016

Study Completion Date

December 31, 2018

Conditions
Intra-dialytic Hypotension
Interventions
DRUG

Mannitol (20%)

0.25g/kg/hour (maximum rate 25g/hour; maximum 75g per session; maximum volume 375mLs per session)

DRUG

0.9% saline

1.25mL/kg/hour; maximum 125mLs/hour; maximum total volume 375mLs per treatment

Trial Locations (1)

02115

Brigham and Women's Hospital, Boston

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER

NCT01520207 - Mannitol - Potential Role in Hemodialysis Initiation for Reduction of Intra-dialytic Hypotension | Biotech Hunter | Biotech Hunter